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Abstract
Background: The epidemics of HIV and hypertension are converging in sub-Saharan Africa. Due to antiretroviral
therapy (ART), more HIV-infected adults are living longer and gaining weight, putting them at greater risk for
hypertension and kidney disease. The relationship between hypertension, kidney disease and long-term ART among
African adults, though, remains poorly defined. Therefore, we determined the prevalences of hypertension and
kidney disease in HIV-infected adults (ART-naive and on ART >2 years) compared to HIV-negative adults.
We hypothesized that there would be a higher hypertension prevalence among HIV-infected adults on ART, even
after adjusting for age and adiposity.
Methods: In this cross-sectional study conducted between October 2012 and April 2013, consecutive adults
(>18 years old) attending an HIV clinic in Tanzania were enrolled in three groups: 1) HIV-negative controls,
2) HIV-infected, ART-naive, and 3) HIV-infected on ART for >2 years. The main study outcomes were hypertension
and kidney disease (both defined by international guidelines). We compared hypertension prevalence between
each HIV group versus the control group by Fisher’s exact test. Logistic regression was used to determine if
differences in hypertension prevalence were fully explained by confounding.
Results: Among HIV-negative adults, 25/153 (16.3%) had hypertension (similar to recent community survey data).
HIV-infected adults on ART had a higher prevalence of hypertension (43/150 (28.7%), P = 0.01) and a higher odds of
hypertension even after adjustment (odds ratio (OR) = 2.19 (1.18 to 4.05), P = 0.01 in the best model). HIV-infected,
ART-naive adults had a lower prevalence of hypertension (8/151 (5.3%), P = 0.003) and a lower odds of hypertension
after adjustment (OR = 0.35 (0.15 to 0.84), P = 0.02 in the best model). Awareness of hypertension was ≤25% among
hypertensive adults in all three groups. Kidney disease was common in all three groups (25.6% to 41.3%) and
strongly associated with hypertension (P <0.001 for trend); among hypertensive participants, 50/76 (65.8%) had
microalbuminuria and 20/76 (26.3%) had an estimated glomerular filtration rate (eGFR) <60 versus 33/184 (17.9%)
and 16/184 (8.7%) participants with normal blood pressure.
Conclusions: HIV-infected adults on ART >2 years had two-fold greater odds of hypertension than HIV-negative
controls. HIV-infected adults with hypertension were rarely aware of their diagnosis but often have evidence of kidney
disease. Intensive hypertension screening and education are needed in HIV-clinics in sub-Saharan Africa. Further studies
should determine if chronic, dysregulated inflammation may accelerate hypertension in this population.
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Background
High blood pressure is the leading risk factor for disease
worldwide and accounts for 7% of global disability-adjusted
life years (DALYs) and nearly 10 million deaths per year
[1]. Despite global declines in blood pressure, the blood
pressures of adults in sub-Saharan Africa (SSA) continue
to rise [2,3], and the age-adjusted prevalence of hyperten-
sion in SSA is estimated to be the highest of any region in
the world [4,5].
HIV remains common in SSA where 69% of HIV-
infected persons reside and one in every twenty adults
is infected [6]. With half of the eligible HIV-infected
persons in SSA on antiretroviral therapy (ART) as of
2010 [7], the infection-related mortality rates have begun
to decline and life expectancy has increased [8], which will
likely mean more cardiovascular disease mortality among
HIV-infected adults as already seen in developed countries
[9,10]. On a population level, in regions with high HIV
prevalence, ART-related weight gain among large num-
bers of HIV-infected adults could lead to an ‘unmasking’
of an epidemic of hypertension and an overall increase in
the prevalence of cardiovascular diseases [11].
The impact of HIV and ART on hypertension remains
controversial. A recent systematic review and meta-analysis
found that HIV-infected adults in SSA generally have lower
blood pressures than uninfected adults [12], and a large,
population-based study from South Africa showed that
hypertension (particulary stage 2 hypertension) was less
common among HIV-infected adults [13], but both
studies noted that data were lacking for HIV-infected
adults on long-term ART in SSA. ART could lead to
hypertension due to weight gain, ART drug toxicities
or through an immune-related phenomenon. In the US
and Europe, some studies have confirmed higher rates
of hypertension among HIV-infected adults on ART
compared to uninfected adults [14], but most studies
have shown no difference [12,15-18]. In two recent
studies from SSA, the prevalence of hypertension among
HIV-infected adults was high but, since only HIV-infected
adults were enrolled, it remains unclear whether this was
due to HIV infection, ART or simply a high community-
wide prevalence of hypertension [19,20]. In addition, al-
though our prior work demonstrated that kidney disease is
common among HIV-infected adults in our region [21,22],
the relationship between hypertension and kidney disease
(which can be a complication of hypertension, a cause of
secondary hypertension or a complication of HIV or ART)
remains unknown.
In view of the existing gap in knowledge, we con-
ducted this prospective study to assess the prevalence
of hypertension and kidney disease among: 1) HIV-
infected, ART-naive adults, 2) HIV-infected adults on
ART for >2 years and 3) HIV-negative adults (controls)
drawn from the same population. We hypothesized that,
compared to HIV-negative controls, hypertension would
be more common among HIV-infected adults on ART
(even after adjusting for confounders) and would be
frequently associated with kidney disease.
Methods
Study design
This was a cross-sectional study designed to compare the
prevalence of hypertension between HIV-negative adults
and two groups of HIV-infected adults.
Study area
The study was conducted in the outpatient HIV clinic of
the Bugando Medical Centre (BMC) in Mwanza, Tanzania.
BMC is the zonal hospital for the Lake Victoria Zone in
northwest Tanzania, serving a population of approximately
13 million. The HIV prevalence in the Lake Zone is 6%
[23], similar to the national average. The BMC HIV clinic
provides care to 3,500 patients of whom 2,700 are currently
on ART. Patients are referred to BMC from surrounding
community-based voluntary counseling and testing centers
in the city of Mwanza. According to Tanzanian national
guidelines, all HIV-infected patients must be assigned
a treatment partner who is typically a family member,
friend or partner.
HIV-infected patients fulfilling Tanzanian national criteria
for ART are started on treatment and are seen monthly or
bi-monthly at the BMC clinic. At the time of the study,
Tanzanian criteria for starting ART included World Health
Organization (WHO) Clinical Stage III disease with
CD4 count <350 cells/μl, Stage IV disease regardless of
CD4 count, or CD4 count <200 cells/μl. The first-line ART
regimen consisted of either tenofovir/emcitrabine or
zidovudine/lamivudine + nevirapine or efavirenz. Protease
inhibitors (PIs) were only given as second-line ART, in ac-
cordance with Tanzanian national guidelines [24].
Study population
Three study groups of non-pregnant adults (>18 years old)
were recruited from the BMC HIV clinic:
1. HIV-negative adult treatment partners
(the control group),
2. HIV-infected adults enrolled in the last three
months and not yet on ART (the HIV-infected,
ART-naive group), and
3. HIV-infected adults on ART for >2 years
(the HIV-infected, on ART group).
Consecutive HIV-infected adults who met the criteria
for study groups 2 or 3 were asked to participate and, if
they agreed, their treatment partners were asked to
participate in the HIV-negative control group in order to
provide a control population with similar socioeconomic
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status to the two groups of HIV-infected adults. Pregnant
women were not eligible for the study. Adults who failed
to attend a follow-up visit on the day after enrollment
were excluded.
Study procedure
On the day of enrollment, the WHO STEPS questionnaire
was administered by the study investigators to determine
the prevalence of hypertension and hypertension risk
factors [25]. The WHO STEPS questionnaire includes
questions regarding prior hypertension testing/diagnosis/
treatment, other non-communicable disease and standard
protocols for physical examination (as described below).
Additional questions were added regarding HIV diagnosis
and treatment.
After completing the questionnaire, we conducted a phys-
ical examination, including weight and height to assess body
mass index (BMI) and waist and hip circumferences. We
measured weight to the nearest 0.1 kg using a digital Seca®
813 weight measuring scale (Seca, Hamburg, Germany)
with participants wearing minimal clothing and shoes re-
moved. Height was measured to the nearest 0.1 cm using a
Seca® 213 stadiometer. Waist and hip circumferences were
measured twice to the nearest 0.1 cm using a 203 cm Seca®
measuring tape. For each of these measurements, the mean
of the two values was used.
Blood pressure was measured at least three times over
the course of two days by a registered nurse or doctor
using a mercury sphygmomanometer. All blood pressure
measurements were taken after five minutes of resting
quietly and study subjects sat with arm supported at the
level of the heart. On the day of enrollment, in accordance
with the WHO STEPS protocol [25], at least two measure-
ments were taken one minute apart on alternating arms. If
there was >10 mmHg difference in either the systolic and/
or diastolic readings, comparing these two readings, further
readings were taken until two consecutive measurements
were concordant within this range. Average systolic and
diastolic pressures were calculated from the last two read-
ings. An additional blood pressure measurement was made
on the following day using the same procedure.
Laboratory analysis
At the time of enrollment, venous blood and a clean-catch
urine sample were obtained. The CD4 T-cell count was
measured using an automated BD FACS Calibur Machine
(BD Biosciences, San Jose, CA, USA). A serum creatinine
level was measured using Cobas Integra 400 Plus Analyzer
(Roche Diagnostic Limited, Basel, Switzerland). An esti-
mated glomerular filtration rate (eGFR) was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (without ethnic factor) since this equa-
tion is recommended by internationally-recognized Kidney
Disease Improving Global Outcomes (KDIGO) guidelines
and has been shown to be the most accurate eGFR equa-
tion for African adults [26-28]. Urine samples were
tested for microalbuminuria using Micral B Test Strips
(Roche, Mannheim, Germany) as used in our prior
studies [21,29]. In order to maximize our specificity, we
defined microalbuminuria as a urine albumin concentra-
tion of >50 mg/L [30]. In women whose last menstrual
period was >1 month prior to the date of study interview,
a urine pregnancy test was performed.
Definitions
The primary outcome of this study was hypertension.
Hypertension was defined as a sustained elevation of
systolic blood pressure (SBP) ≥140 mmHg and/or dia-
stolic blood pressure (DBP) ≥90 mmHg on two different
days or current antihypertensive therapy, according to
the Joint National Committee 7 (JNC-7) definition [31].
The grade of hypertension was also defined according to
JNC-7 using the average of three blood pressure read-
ings: normal is SBP <120 mmHg and DBP <80 mmHg,
prehypertension is SBP 120 to 139 mm Hg or DBP 80 to
89 mm Hg, Stage I hypertension is SBP 140 to 159 mm
Hg or DBP 90 to 99 mm Hg and Stage II hypertension
is SBP >160 mm Hg or DBP >100 mm Hg.
Central obesity was defined as a waist-hip ratio of ≥0.85
for women and waist-hip ratio ≥0.90 for men according to
the WHO [25]. Chronic Kidney Disease (CKD) was defined
as eGFR <60 mL/minute and/or microalbuminuria accord-
ing to KDIGO [26].
Statistical analysis
The primary outcome of the study was hypertension
(as defined above). The primary study analysis was to
compare the prevalence of hypertension between each
HIV-infected group and the HIV-negative control group. Ac-
cording to a recent population-based survey, 17% of adults
in Mwanza city have hypertension (Kavishe BB, Mwanza
Interventional Trials Unit, personal communication) and we
hypothesized that 30% of HIV-infected adults on ART would
have diabetes mellitus. Using Fishers exact test, we calculated
that 150 patients in each group would provide 80% power to
detect this difference for P <0.05.
Data analysis was done using STATA version 11 (San
Antonio, TX, USA). Descriptive statistics were computed
by determining median [interquartile range] for continuous
variables and proportions (percentages) for categorical
variables. Differences between medians were deter-
mined using the rank sum test and differences between
proportions were determined using Fisher’s exact test.
For ordered categorical variables, the nonparametric
test for trend was used. P-values of less than 0.05 were
considered significant.
Multiple logistic regression models were performed in
order to determine whether the relationship between HIV
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status and hypertension could be explained by con-
founding. All baseline characteristics, including past or
current exposure to individual ART drugs, were evalu-
ated by a pre-determined, minimally adjusted logistic
regression model adjusting for age and sex (since these
were expected to differ between groups). Additional,
pre-determined multivariable analyses were performed
to adjust for BMI and waist-hip ratio (since these were
the factors most highly expected to explain differences
in hypertension prevalence between groups) as well as
fully-adjusted models including all variables with a P-value
of <0.05 by minimally adjusted multivariate analysis. BMI
and waist-hip ratio were not included together in any
models due to collinearity. Variables associated with HIV
infection and ART use were not included in the multivari-
able models due to collinearity with the group variables
and the smaller number of subjects with these additional
variables. For associated factors, odds ratios (OR) and 95%
confidence intervals (95% CI) were determined. The likeli-
hood ratio test was used to compare the logistic regression
models. We also performed multivariable linear regression
to determine factors associated with increased SBP and
DBP, including all of the same variables that were included
in the best-fit multivariable logistic regression model.
Ethical issues
The study was approved by the Institutional Review
Boards at BMC and Weill Cornell Medical College. All
study participants were informed about the study by a
nurse or doctor fluent in Kiswahili and provided written
informed consent before participation. All results were
made available to clinicians and recorded in the patient’s
file. Disease management was conducted by the health
care workers of the HIV clinic according to BMC and
Tanzanian management protocols.
Results
Enrollment
Between October 2012 and April 2013, 488 consecutive
adults were screened. Seven were pregnant (three HIV-
infected ART-naive and four HIV-infected on ART),
leaving 481 eligible adults. A total of 454/481 (94%) of
eligible adults were enrolled: 153 HIV-negative adults
(controls), 151 HIV-infected ART-naive adults and 150
HIV-infected adults on ART. Twenty-seven were excluded
from the study because they did not return for follow-up
testing (eleven HIV-negative controls, nine HIV-infected
ART-naive, seven HIV-infected on ART).
Baseline characteristics
Table 1 is a summary of the baseline characteristics of the
three groups.
The characteristics of the three groups were broadly
similar. Notable differences included that HIV-infected
adults on ART were slighly older (median age 40 [38 to 47]
years versus 38 [32 to 46] years and 37 [32 to 44] years in
the other two groups), more female (76.7% versus 61.4%
and 58.9% in the other two groups) and had a higher preva-
lence of central obesity (52.0% versus 29.1% and 37.1%).
HIV-infected, ART-naive adults, on the other hand, had
lower mean BMI (22.0 [20.2 to 24.3] kg/m2 versus 23.8
[22.3 to 25.8] and 23.7 [21.5 to 27.9]) and were severely im-
munosuppressed (mean CD4 T-cell count 215 [150 to 321]
cells/ul versus 378 [263 to 521] in the group on ART).
Hypertension outcomes
Table 2 shows hypertension outcomes in the three groups.
The prevalence of hypertension in the 153 HIV-negative
controls was 25/153 (16.3%). The prevalence of hypertension
was lowest in the 151 HIV-infected, ART-naive group
(8/151 (5.3%), P= 0.003) and highest in the 150 HIV-infected
adults on ART >2 years (43/150 (28.7%), P= 0.01). The me-
dian SBP and DBP were both lower in the HIV-infected,
ART-naive group (P = 0.007 and P = 0.04, respectively). The
grade of hypertension was also higher among the HIV-
infected adults on ART versus controls (P = 0.01 for trend).
Rates of hypertension awareness ranged from 3/25
(12%) and 1/8 (12.5%) in the control and HIV-infected,
ART-naive group to 11/43 (25.6%) in the HIV-infected
on ART group. Rates of current hypertension treatment
ranged from none in the control and HIV-infected,
ART-naive groups to 7/43 (16.3%) in the HIV-infected
on ART group. Rates of hypertension control ranged from
none in the control and HIV-infected, ART naive groups to
1/43 (2.3%) in the HIV-infected on ART group. Among
HIV-negative controls, 86/153 (56.2%) reported never hav-
ing had their blood pressure checked and only 40/153
(26.1%) reported having their blood pressure checked within
the last year. Rates of prior blood pressure testing were simi-
lar in HIV-infected, ART-naive adults (83/151 (55.0%) never
checked and 41/151 (27.2%) checked in last year, P= 0.82)
but slightly higher among HIV-infected adults on ART
(64/150 (42.7%) and 47/150 (31.3%) respectively, P = 0.04).
Factors associated with hypertension
Table 3 shows the factors associated with hypertension
by predetermined, partially adjusted multivariable analysis
(adjusted for age and sex). As shown, age (OR = 1.07 [1.04
to 1.09]), vigorous work (OR = 0.33 [0.13 to 0.88]), current
alcohol use ≥ once/week (OR = 0.13 [0.02 to 0.99]), and
BMI (OR = 1.09 [1.03 to 1.15]) were all associated with
hypertension. Current CD4 T-cell count (OR = 4.33
[1.51 to 12.40] for CD4 T-cell count >500cells/μL ver-
sus <200cells/μL) was also significantly associated with
hypertension. Of note, the current CD4 T-cell count was
also associated with both SBP and DBP by linear regres-
sion (β = 0.022 [0.014 to 0.029], P <0.001 and β = 0.011
[0.006 to 0.017], P <0.001, respectively).
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Among variables that were only available for HIV-
infected adults on ART, only the use of protease inhibitors
(OR = 3.14 [1.10 to 8.98]) was significantly associated with
hypertension by logistic regression adjusted for age and sex.
The following variables were not significantly associated
with hypertension: duration of ART (OR = 1.017 [0.999 to
1.034]), zidovudine use (OR = 0.81 [0.39 to 1.70]), stavudine
use (OR = 0.97 [0.46 to 2.04]), tenofovir use (OR = 1.26
Table 1 Baseline characteristics of the 454 Tanzanian adult study participants
Variable HIV-negative HIV-infected, HIV-infected,
Proportion (%) control ART-naive on ART
Median [IQR] (number = 153) (number = 151) (number = 150)
Female 94 (61.4%) 89 (58.9%) 115 (76.7%)
Age (in years) 38 [32 to 46] 37 [32 to 44] 40 [38 to 47]
Education level
Incomplete primary 27 (17.7%) 25 (16.6%) 30 (20.0%)
Complete primary 82 (53.6%) 98 (64.9%) 94 (62.7%)
Secondary and above 44 (28.8%) 28 (18.5%) 26 (17.3%)
Work type
Manual 109 (71.2%) 114 (75.5%) 105 (70.0%)
Office 44 (28.8%) 37 (24.5%) 45 (30.0%)
Vigorous work 15 (9.8%) 21 (13.9%) 33 (22.0%)
Mode of transportation
Walking or bicycle 130 (85.0%) 110 (72.9%) 117 (78.0%)
Motorized vehicle 23 (15.0%) 41 (27.1%) 33 (22.0%)
Ease of Living Indexa
Low 86 (56.2%) 94 (62.3%) 81 (54.0%)
Middle 20 (13.1%) 24 (15.9%) 26 (17.3%)
Higher 47 (30.7%) 33 (21.9%) 43 (28.7%)
Ever smoking 6 (3.9%) 16 (10.6%) 10 (6.7%)
Current smoker 5 (3.3%) 4 (2.7%) 0
Fruit and vegetables servings/week 6 [4-12] 8 [5-12] 9 [6 to 13]
Sugary drinks/day 1 [0.5 to 2] 1 [0.5 to 2] 1 [1 to 2]
Current alcohol use
None 119 (77.8%) 120 (79.5%) 136 (90.7%)
< once/week 19 (12.4%) 16 (10.6%) 8 (5.3%)
≥ once/week 15 (9.8%) 15 (9.9%) 6 (4.0%)
Body Mass Index (BMI) in kg/m2 23.8 [22.3 to 25.8] 22 [20.2 to 24.3] 23.7 [21.5 to 27.9]
BMI <18.5 5 (3.3%) 18 (11.9%) 4 (2.7%)
BMI 18.5 to 25 104 (68.0%) 113 (74.8%) 80 (53.3%)
BMI 25 to 30 33 (21.6%) 9 (6.0%) 45 (30.0%)
BMI >30 11 (7.2%) 11 (7.3%) 21 (14.0%)
Waist-hip ratio 0.84 [0.82 to 0.87] 0.84 [0.80 to 0.89] 0.87 [0.82 to 0.91]
Central obesityb 44 (29.1%) 56 (37.1%) 78 (52.0%)
Diabetes mellitus 0 1 (0.7%) 1 (0.7%)
Current CD4 T-cell count in cells/μL NA 215 [150 to 321] 378 [263 to 521]
Nadir CD4 T-cell count in cells/μL NA 209 [120 to 302] 118.5 [68 to 196]
ART duration (months) NA NA 56 [31 to 68]
Protease inhibitor use NA NA 18 (12.0%)
aEase of Living Index was defined according to the presence of water, electricity and/or flushing toilets inside the home. Low = 0/3, Medium= 1 to 2/3, Higher = 3/3.
bDefined as waist-hip ratio of ≥0.85 for women and waist/hip ratio ≥0.90 for men. ART, antiretroviral therapy; IQR, interquartile range.
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[0.59 to 2.70]), efavirenz use (OR = 0.84 [0.39 to 1.75]), and
nevirapine use (OR = 1.13 [0.51 to 2.51]).
Table 4 displays the multivariable models used to esti-
mate the impact of HIV and ART status on hypertension
status. HIV-infected adults on ART had a significantly
higher risk of hypertension than HIV-negative con-
trols, even after adjusting for differences in age and sex
(OR = 2.13 [1.18 to 3.85]). Further adjustment for BMI,
waist-to-hip ratio, vigorous work and alcohol use did
not change these estimates. In contrast, HIV-infected,
ART-naive adults had a significantly lower risk of hyper-
tension, even after adjustment for difference in age and
sex (OR = 0.32 [0.14 to 0.75]). Further adjustment for
BMI, waist-to-hip ratio, vigorous work and alcohol use
did not change these estimates. The likelihood ratio test
showed that the model with HIV and ART status, along
with age, sex, BMI, vigorous work and alcohol use, best
explained the differences in hypertension in this study. By
linear regression, adjusting for age, sex, BMI, vigorous
work and alcohol use, the HIV-infected, ART-naive group
had lower SBP and DBP, but this was only statistically
significant for SBP (β = −3.84 [−6.89 to −0.79], P = 0.01
and β = −1.96 [−4.09 to 0.17], P = 0.07 respectively).
The HIV-infected on ART group had higher SBP and
DBP, but this was not statistically significant for either
(β = 1.32 [−1.85 to 4.48], P = 0.41 and β = 1.27 [−0.93 to
3.48], P = 0.26, respectively).
Renal disease outcomes
Table 5 displays the renal disease outcomes among the
454 study participants. The overall prevalence of chronic
kidney disease among the 153 HIV-negative controls
was 25.6%. Among the 150 HIV-infected adults on
ART >2 years, the prevalence of chronic kidney disease
was 41.3% (P = 0.004 versus the control group) and micro-
albuminuria was also more common than among controls
(58/150 (38.7%) versus 31/153 (20.3%), P = 0.001). None
of the commonly used antiretrovirals (ARVs) were signifi-
cantly associated with chronic kidney disease by Fisher’s
exact test (P = 0.73 for tenofovir, P = 0.87 for zidovudine,
P = 0.40 for stavudine, P = 1.00 for nevirapine, P = 1.00 for
efavirenz, P = 0.08 for protease inhibitors,).
Table 6 shows the association between kidney disease
and grade of hypertension both overall and in each of
the three study groups. Overall, higher grades of hyper-
tension were associated with higher rates of kidney dis-
ease, microalbuminuria and eGFR <60 (P <0.0001 for
trend for all three variables). Similar trends were seen
in all three study groups.
Discussion
We found that the prevalence of hypertension is high
(nearly 30%) among HIV-infected Tanzanian adults on
ART for >2 years. In our study, HIV-infected adults on
ART had twice the odds of hypertension as HIV-negative
controls, even after adjusting for potential confounders,
such as age, sex, BMI, waist-hip ratio and vigorous work.
HIV-infected adults on ART not only had more hyperten-
sion than controls, but also had more severe hypertension
(Grade II hypertension – 7% versus 3% of controls).
The average blood pressures were not higher among
HIV-infected adults on ART, but this is likely because
more of the patients in this group were on antihyper-
tensive medications, leading to a reduction in the mean
blood pressures. To the best of our knowledge, this is
the first study to compare hypertension prevalence be-
tween HIV-infected African adults on long-term ART
to HIV-negative adults.
The high prevalence of hypertension among HIV-infected
adults on ART could be related to dysregulated inflam-
mation due to immune reconstitution. Inflammation is
well recognized as a major part of the pathophysiology
of hypertension [32]. Activated CD4+ T-cells infiltrate the
kidney and vascular walls in animal models of hypertension
Table 2 Hypertension outcomes among the 454 Tanzanian adult study participants
Variable HIV-negative HIV-infected, P-value HIV-infected, P-value
Proportion (%) control ART-naïve versus on ART versus
Median [IQR] (number = 153) (number = 151) control (number = 150) control
Hypertensiona 25 (16.3%) 8 (5.3%) 0.003b 43 (28.7%) 0.01
Systolic blood pressure 120 [110 to 130] 115 [110 to 120] 0.007 120 [110 to 137.5] 0.16
Diastolic blood pressure 75 [70 to 80] 75 [70 to 80] 0.04 80 [70 to 90] 0.11
Heart rate 73 [70 to 77] 74 [70 to 79] 0.35 74 [69.5 to 85] 0.18
Hypertension grade P-value for trend P-value for trend
Normal 66 (43.1%) 69 (45.7%) 49 (32.7%)
Prehypertension 62 (40.5%) 74 (49.0%) 0.16 58 (38.7%) 0.01
Grade 1 hypertension 20 (13.1%) 7 (4.6%) 33 (22.0%)
Grade 2 hypertension 5 (3.3%) 1 (0.7%) 10 (6.7%)
aPrimary outcome: hypertension defined as average SBP >140 and/or DBP >90 and/or currently taking antihypertensive medications. bThroughout the tables,
bolding has been used to indicate those p-values and odds ratios which were statistically significant. ART, antiretroviral therapy; IQR, interquartile range.
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Table 3 Factors associated with hypertension among 454 Tanzanian adults by multivariable logistic regression
adjusted for age and sex
Variable No hypertension Hypertension Odds ratio [95% CI]
Proportion (%) (number = 378) (number = 76)
Median [IQR]
Female 251 (66.4%) 47 (61.8%) 1.10 [0.64 to 1.91]
Age (in years) 38 [32 to 44] 45 [39.5 to 52] 1.07 [1.04 to 1.09]
Education level
Incomplete primary 72 (19.1%) 10 (13.2%) 1
Complete primary 221 (58.5%) 53 (69.7%) 2.09 [0.97 to 4.50]
Secondary and above 85 (22.5%) 13 (82.9%) 1.57 [0.61 to 4.02]
Work type
Manual 274 (72.5%) 54 (71.1%) 1
Office 104 (27.5%) 22 (29.0%) 1.08 [0.62 to 1.91
Vigorous work 64 (16.9%) 5 (6.6%) 0.33 [0.13 to 0.88]
Transportation
Walking or bicycle 301 (79.6%) 56 (74.7%) 1
Motorized vehicle 77 (20.4%) 20 (26.3%) 1.32 [0.73 to 2.39]
Ease of Living Index
Low 219 (57.9%) 42 (55.3%) 1
Middle 54 (14.3%) 16 (21.1%) 1.96 [0.99 to 3.91]
Higher 105 (27.8%) 18 (23.7%) 0.96 [0.52 to 1.79]
Ever smoking 26 (6.9%) 6 (7.9%) 1.02 [0.37 to 2.76]
Current smoker 7 (1.9%) 2 (2.6%) 1.41 [0.25 to 8.14]
Fruit and vegetables servings/week 8 [5 to 12] 9 [5 to 13] 1.02 [0.98 to 1.06]
Sugary drinks/day 1 [1,2] 1 [0.5 to 2] 1.17 [0.98 to 1.40]
Current alcohol
None 307 (81.2%) 68 (89.5%) 1
< once/Week 36 (9.5%) 7 (9.2%) 0.77 [0.31 to 1.89]
≥ once/Week 35 (9.3%) 1 (1.3%) 0.13 [0.02 to 0.99]
Body Mass Index (BMI) in kg/m2 22.9 [20.9 to 25.1] 24.2 [22.3 to 28.2] 1.09 [1.03 to 1.15]
BMI <18.5 25 (6.6%) 2 (2.6%) 1
BMI 18.5 to 25 255 (67.5%) 42 (55.3%) 1.53 [0.34 to 6.84]
BMI 25 to 30 67 (17.7%) 20 (26.3%) 3.39 [0.73 to 15.77]
BMI >30 31 (8.2%) 12 (15.8%) 3.40 [0.67 to 17.15]
Waist-to-Hip Ratio 0.84 [0.81 to 0.89] 0.86 [0.83 to 0.91] 1.03 [0.98 to 1.08]
for each 0.01 increase
Central obesitya 142 (37.6%) 36 (47.4%) 1.54 [0.90 to 2.64]
Current CD4 T-cell
count (in cells/μL)b
267.5 [180 to 385] 453 [323 to 590] 1.003 [1.002 to 1.005]
for each cell/μL
<200 71 (28.4%) 6 (11.8%) 1
200 to 350 98 (39.2%) 10 (19.6%) 0.88 [0.30 to 2.63]
350 to 500 46 (18.4%) 15 (29.4%) 2.44 [0.85 to 7.01]
>500 35 (14.0%) 20 (39.2%) 4.33 [1.51 to 12.40]
aDefined as waist/hip ratio of ≥0.85 for women and waist/hip ratio ≥0.90 for men. bFor all 301 study subjects with HIV including 50 with hypertension and 250
without hypertension. CI, confidence interval; IQR, interquartile range.
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[33]. In our study, among HIV-infected adults, the higher
CD4+ T-cell counts were associated with more hyperten-
sion and higher blood pressures. The prevalence of hyper-
tension was lowest in the group with the lowest average
CD4+ T-cell count (HIV-infected ART-naive) and highest
in the group in which the CD4+ T-cell count had been low
and had then been reconstituted in the setting of ART.
Chronic immune activation, including elevated proportions
of activated CD4+ and CD8+ T-cells and of T-regulatory
cells, irreversible loss of gut mucosal integrity and later
destruction of lymph nodes, is known to be common
among HIV-infected adults [34-36], and may play a key
role in the pathophysiology of hypertension among
HIV-infected adults on ART in SSA. Chronic inflam-
mation has been shown to persist even after initiation
of ART [37]. Even HIV-uninfected adults living in Africa
have higher levels of immune activation than their coun-
terparts living in resource-rich settings [38,39], suggesting
that hypertension among adults in SSA, and particularly
those with HIV infection on ART, may serve as a model
for inflammation-induced hypertension in humans. In
order to further test this hypothesis, prospective studies
are needed to determine the trajectory of blood pressure
changes after ART initiation and associated immuno-
logic and inflammatory markers.
Another possible cause of the higher prevalence of
hypertension observed among HIV-infected individuals
on ART is a direct or indirect effect of the ARV drugs,
but we do not think that this is likely to be the primary
explanation. In our study, the duration of ART use was
not associated with hypertension. Protease inhibitor use
was indeed associated with hypertension but only 10% of
subjects had received protease inhibitors and other ARV
drugs were not associated with hypertension. Moreover,
although protease inhibitor use has been associated with
hypertension in one prior study [15], most studies showed
no association [17,19]. In fact, the majority of studies of
hypertension among HIV-infected adults on ART have
shown no association between hypertension and ART
use, regardless of drug class [12,15-18].
We found that the prevalence of hypertension among
HIV-infected, ART-naive adults is low (5%). HIV-infected,
ART-naive adults had 65% lower odds of having hyperten-
sion when compared to HIV-negative controls, even after
controlling for possible confounders, such as age, sex,
BMI, waist-to-hip ratio and vigorous work. The lower
Table 4 Multivariable logistic regression models for association between HIV status and hypertension to assess
for confounding
Model Controls
(number = 153)
HIV-infected,
ART naive
P-value
versus
control
HIV-infected,
on ART
P-value
versus
control
Likelihood ratio
test (compared to
unadjusted model)(number = 151) (number = 150)
1) Unadjusted 1 0.28 [0.12 to 0.66] 0.003 2.06 [1.18 to 3.59] 0.01 0
2) Adjusted for age + sex 1 0.32 [0.14 to 0.75] 0.009 2.13 [1.18 to 3.85] 0.01 21.7, 2 d.f.
3) Adjusted for age + sex +
body mass index (BMI)
1 0.34 [0.14 to 0.79] 0.01 2.04 [1.12 to 3.67] 0.02 25.7, 3 d.f.
4) Adjusted for age + sex +
waist-hip ratio (WHR)
1 0.31 [0.13 to 0.73] 0.007 2.04 [1.12 to 3.71] 0.02 22.2, 3 d.f.
5) Adjusted for age + sex +
BMI + vigorous work + alcohol
1 0.35 [0.15 to 0.84] 0.02 2.19 [1.18 to 4.05] 0.01 37.7, 5 d.f.a
6) Adjusted for age + sex +
WHR+ vigorous work + alcohol
1 0.32 [0.14 to 0.77] 0.01 2.19 [1.17 to 4.10] 0.01 35.4, 5 d.f.
aBest fit model. All models are comparing to HIV-negative controls. Models 1, 2, 3 and 4 were predetermined based on most likely confounders. Models 5 + 6
included other baseline characteristics significantly associated with hypertension in the minimally-adjusted model. ART, antiretroviral therapy.
Table 5 Kidney disease outcomes among the 454 Tanzanian adult study participants
Variable HIV-negative
controls
HIV-infected,
ART-naive
P-value versus
control
HIV-infected,
on ART
P-value versus
controlProportion (%)
Median [IQR] (number = 153) (number = 151) (number = 150)
Kidney diseasea 39 (25.6%) 52 (34.4%) 0.09 62 (41.3%) 0.004
Creatinine (mmol/L) 68.3 [55.6 to 81.1] 70.9 [57.9 to 89] 0.49 64.3 [54.7 to 81.8] 0.69
eGFR 106.5 [78.8 to 119.3] 104.9 [79.9 to 116.7] 0.62 104.4 [82.1 to 115.6] 0.67
eGFR <60 mL/min 20 (13.1%) 19 (12.6%) 0.89 16 (10.7%) 0.52
Microalbuminuria 31 (20.3%) 43 (28.5%) 0.10 58 (38.7%) 0.001
aThe primary kidney disease outcome: defined as microalbuminuria and/or eGFR <60 mL/min. ART, antiretroviral therapy; eGFR, estimated glomerular filtration
rate; IQR, interquartile ratio.
Peck et al. BMC Medicine 2014, 12:125 Page 8 of 11
http://www.biomedcentral.com/1741-7015/12/125
blood pressures that we observed among HIV-infected,
ART-naive adults is consistent with the results of a re-
cent, large meta-analysis that showed that HIV-infected
adults in SSA (most not on ART) had lower systolic and
diastolic blood pressures than controls [12]. The lower
rates of hypertension among HIV-infected, ART-naive
adults may be explained by HIV-mediated immunosuppres-
sion such that immune reconstitution, after the initiation of
ART, causes ‘unmasking’ of hypertension in susceptible
individuals. Other explanations, such as dysregulation
of the sympathetic nervous system, HIV-related hypoa-
drenalism and side effects of traditional, herbal medicines,
have also been proposed [11,16,17].
We also noted low rates of hypertension diagnosis,
treatment and control. Even among HIV-infected adults
who were regularly attending the HIV clinic to receive
ART, the rates of hypertension awareness, treatment and
control were 25%, 15% and 2%, respectively, and only
30% reported undergoing blood pressure measurement
in the last year. Similarly low rates of awareness, treat-
ment, control and testing have been described among
community-dwelling adults in other parts of SSA [40,41],
but one might expect that the situation would be better in
the context of ongoing HIV care. Possibly, the low
hypertension prevalence observed before ART initiation
may be creating a false sense of security with regard to
hypertension risk among HIV-infected patients and
their care-providers. It is also possible that ART may re-
duce the effectiveness of anti-hypertensive medications
(although this is unlikely to be a major factor in our
study since very few of our subjects were taking anti-
hypertensive medications at the time of enrollment).
On the other hand, HIV care provides a good opportunity
for chronic hypertension management [20], and regular
blood pressure measurement should be considered an
essential element of HIV care as we are now seeking to
reinforce in our own HIV clinic. Studies from South Africa
have shown that, when non-communicable disease care is
integrated into HIV care, HIV-infected adults on ART can
attain even better functional ability and health status than
the general population [37,42].
Of note, hypertension was also strongly associated
with markers of kidney disease in all three study groups;
among the 76 total adults with hypertension, 50 (65.8%)
had microalbuminuria and 20 (26.3%) had eGFR <60. These
findings suggest that the hypertension that we observed in
Table 6 Association between kidney disease and grade of hypertension among all 454 Tanzanian adult study
participants and in each of the three study groups
Among 454 Tanzanian adult study participants
Normal Prehypertension Hypertension Grade 1 Hypertension Grade 2 P-value for trend
(number = 184) (number = 194) (number = 60) (number = 16)
Kidney Diseasea 44 (23.9%) 58 (29.9%) 40 (66.7%) 11 (68.8%) <0.001
Microalbuminuria 33 (17.9%) 49 (25.3%) 40 (66.7%) 10 (62.5%) <0.001
eGFR <60 16 (8.7%) 19 (9.8%) 14 (23.3%) 6 (37.5%) <0.001
Among 153 HIV-negative adults (controls)
Normal Prehypertension Hypertension Grade 1 Hypertension Grade 2 P-value for trend
(number = 66) (number = 62) (number = 20) (number = 5)
Kidney Disease 8 (12.1%) 15 (24.2%) 13 (65.0%) 3 (60.0%) <0.001
Microalbuminuria 4 (6.1%) 12 (19.4%) 13 (65.0%) 2 (40.0%) <0.001
eGFR <60 5 (7.6%) 6 (9.7%) 6 (30.0%) 3 (60.0%) <0.001
Among 151 HIV-infected, ART-naive adults
Normal Prehypertension Hypertension Grade 1 Hypertension Grade 2 P-value for trend
(number = 69) (number = 74) (number = 7) (number = 1)
Kidney Disease 22 (31.9%) 24 (32.4%) 5 (71.4%) 1 (100%) 0.11
Microalbuminuria 16 (23.2%) 21 (28.4%) 5 (71.4%) 1 (100%) 0.02
eGFR <60 8 (11.6%) 9 (12.2%) 2 (28.6%) 0 0.53
Among 150 HIV-infected adults on ART
Normal Prehypertension Hypertension Grade 1 Hypertension Grade 2 P-value for trend
(number = 49) (number = 58) (number = 33) (number = 10)
Kidney Disease 14 (28.6%) 19 (32.8%) 22 (66.7%) 7 (70.0%) <0.001
Microalbuminuria 13 (26.5%) 16 (27.6%) 22 (66.7%) 7 (70.0%) <0.001
eGFR <60 3 (6.1%) 4 (6.9%) 6 (18.2%) 3 (30.0%) 0.01
aThe primary kidney disease outcome: defined as microalbuminuria and/or eGFR <60 mL/min. ART, antiretroviral therapy; eGFR, estimated glomerular
filtration rate.
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our study is not simply a benign, uncomplicated condition.
What remains unclear, however, is whether the hyperten-
sion preceded the kidney disease or vice-versa. Kidney dis-
ease is known to be common among HIV-infected adults
in our region [21] and may be predisposing these adults to
the development of hypertension. The kidney disease that
we observed among HIV-infected adults on ART does not
seem to be related to any specific ART drug based on either
this study or our prior work [22].
Study limitations include that enrollment occurred at
a single HIV clinic. Our results require validation at other
sites. As a government-funded, primary care HIV clinic,
though, our patient population is similar to other HIV
clinics in our region. In addition, some laboratory tests
(such as HIV viral loads) were not available at our cen-
ter during the study period, but our main study results
remain valid even without these variables.
Conclusions
In conclusion, we observed hypertension in nearly 30%
of Tanzanian HIV-infected adults on ART treatment and
these adults had twice the odds of hypertension compared
to HIV-negative controls, even after correcting for differ-
ences in age, sex and adiposity. Among the HIV-infected
adults with hypertension, 75% were undiagnosed, 85% were
untreated and >95% were uncontrolled. Importantly, hyper-
tension was strongly associated with kidney disease in this
population. We suggest that aggressive screening, counsel-
ing and treatment for hypertension should be instituted in
HIV clinics in SSA. Further studies are needed to determine
if this hypertension is due to the ART itself or dysregulated
inflammation due to immune reconstitution.
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